Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

What are Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)?

Anti-PD-1 and PD-L1 monoclonal antibodies are a type of targeted immunotherapy called an immune checkpoint inhibitor. Checkpoint inhibitors don't kill cancer cells directly, instead, they target specific proteins on T-cells (a type of immune cell), one of which is called PD-1.

In healthy people, PD-1 acts as a “set of brakes” to stop the T-cells from attacking other cells in the body. It does this by attaching to PD-L1, a protein on some normal (and cancer) cells. When PD-1 is bound to PD-L1, the T-cell will not attack the other cell. This helps our immune system tell the difference between foreign invaders and healthy tissue.

But some cancer cells have large amounts of PD-L1, which allows them to bind to PD-1 on the T-cell, and avoid being attacked. When the T-cells are bound to the cancer cells, it puts the "brakes" on, and the T-cell can't fight the cancer.

Monoclonal antibodies that target either PD-1 or PD-L1 can block this binding and put the T-cell "brakes" in the “off” position, which means the T-cells are now active to find and kill the cancer cells, wherever they are in the body.

Other types of immune checkpoint inhibitors include those that target other checkpoint proteins such as CTLA-4 and LAG-3. These are typically used in combination with a PD-1 or PD-L1 inhibitor to treat several types of cancer.

All of these drugs are given as an infusion into a vein (IV).

PD-1 inhibitors

Examples of drugs that target PD-1 include:

Cemiplimab (Libtayo)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda).

PD-L1 inhibitors

Examples of drugs that target PD-L1 include:

Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Durvalumab (Imfinzi).

List drug with Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Drug Name
Atezolizumab Generic name: Atezolizumab
Avelumab Generic name: Avelumab
Bavencio Generic name: Avelumab
Cemiplimab Generic name: Cemiplimab
Cemiplimab-rwlc Generic name: Cemiplimab-rwlc
Dostarlimab Generic name: Dostarlimab
Dostarlimab-gxly Generic name: Dostarlimab-gxly
Durvalumab Generic name: Durvalumab
Imfinzi Generic name: Durvalumab
Jemperli Generic name: Dostarlimab-gxly
Keytruda Generic name: Pembrolizumab
Libtayo Generic name: Cemiplimab-rwlc
Nivolumab Generic name: Nivolumab
Opdivo Generic name: Nivolumab
Pembrolizumab Generic name: Pembrolizumab
Retifanlimab Generic name: Retifanlimab
Retifanlimab-dlwr Generic name: Retifanlimab-dlwr
Tecentriq Generic name: Atezolizumab
Zynyz Generic name: Retifanlimab-dlwr

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.